Angiostatin effectively blocks tumor angiogenesis through still poorly understood mechanisms. Given the close association between immune and vascular regulation, we investigated the effects of angiostatin on angiogenesis-associated leukocytes. Angiostatin inhibited the migration of monocytes and, even more markedly, neutrophils. Angiostatin blocked chemotaxis of neutrophils to CXCR2 chemokine receptor agonists (IL-8, MIP-2, and GROα), formyl-Met-Leu-Phe (fMLP), and 12-O-tetradecanoylphorbol 13-acetate, and repressed fMLP-induced mitochondrial activity. Two different angiostatin forms (kringles 1-4 and 1-3) were effective, whereas whole plasminogen had no effect. IL-8, MIP-2, and GROα induced intense angiogenic reactions in vivo, but no angiogenic response to these factors was observed in neutropenic mice, demonstrating an essential role for neutrophils. Angiostatin potently inhibited chemokine-induced angiogenesis in vivo, and consistent with in vitro observations, both angiostatin forms were active and whole plasminogen had little effect. Angiostatin inhibition of angiogenesis in vivo was accompanied by a striking reduction in the number of recruited leukocytes. In vivo, the inflammatory agent lipopolysaccharide also induced extensive leukocyte infiltration and angiogenesis that were blocked by angiostatin. Neutrophils expressed mRNAs for ATP synthase and angiomotin, two known angiostatin receptors. These data show that angiostatin directly inhibits neutrophil migration and neutrophil-mediated angiogenesis and indicate that angiostatin might inhibit inflammation.
T he balance between pro-and antiangiogenic factors regulates both physiological and malignant angiogenesis, from endothelial cell activation to their differentiation into new vessels. Numerous endogenous angiogenesis inhibitors have been discovered and are currently under intensive study for their application as potential anticancer therapies. Substantial excitement has centered on primary tumor-derived angiogenesis inhibitors that prevent the growth of metastases, such as angiostatin (1) . Angiostatin is a circulating proteolytic cleavage product of plasminogen that can suppress the growth of a variety of tumors through an as yet not completely defined mechanism. Several studies have proposed that angiostatin induces selective inhibition of endothelial cell proliferation, migration, induction of endothelial cell cycle arrest, and apoptosis (2) (3) (4) (5) .
Even if the obvious target of antiangiogenic compounds is endothelial cells, an increasing body of evidence indicates that cells from the natural immune system such as monocytes/macrophages are important regulators of angiogenesis (6, 7) . Granulocytes, whose role is frequently underestimated, also appear to play a primary role in the initial phases of the angiogenic process (8, 9) . Previous observations indicated that most angiogenic growth factors do not act univocally on endothelial cells; for example, HIV-Tat, vascular endothelial growth factor (VEGF), and Kaposi's sarcoma cell supernatants are all known to recruit mesenchymal cells and phagocytes into matrigel in vivo (10, 11) . Recent studies on the HIVTat protein have shown that the angiogenic potential of this molecule is linked not only to VEGF mimicry exerted by the basic domain of Tat (12, 13) , but also to recruitment of monocytes and granulocytes in vitro and in vivo via a chemokine-like domain of this molecule (11, 14, 15) . Furthermore, the angiogenic response to laminin peptides in vivo is lacking in neutropenic mice (16) , underscoring the importance of these cells in some angiogenic responses.
The ability of human neutrophils to produce angiogenic cytokines such as VEGF and IL-8 further supports a role for these leukocytes as cellular mediators of the angiogenic process (17) . In addition, neutrophils can be an abundant source of MMP-9 (gelatinase B), an enzyme associated with the vascular switch during tumor development (18, 19) . Although the precise role of neutrophils in tumor development is still uncertain, because their contribution may be time-restricted, they could induce tumor growth by direct promotion of vessel generation under both physiological (wound healing) and pathological (cancer, psoriasis) conditions. To date, studies on the effects of angiostatin have been limited to vascular cells (endothelial and smooth muscle cells); its role in phagocyte control has never been investigated.
Here, we demonstrate that angiostatin is a strong inhibitor of neutrophil migration in vitro and angiogenesis in vivo induced by CXCR2 agonists IL-8, MIP-2, and GROα. These same chemokines were unable to induce angiogenesis in neutropenic mice, directly demonstrating a key role for these cells. Angiostatin also inhibited neutrophil migration to formyl-Met-LeuPhe (fMLP) and 12-O-tetradecanoylphorbol 13-acetate (TPA), suggesting that it interferes with a downstream pathway common to these stimulants. Neutrophils expressed mRNAs for the angiostatin receptors angiomotin (20) and ATP synthase (21) and expressed ATP synthase protein on their surfaces. Furthermore, we observed that the inflammatory stimulus lipopolysaccharide (LPS) rapidly induced angiogenesis in vivo that was inhibited by angiostatin. These studies show that angiostatin acts on a novel cell target, which may be critical in defining the mechanisms of action of angiostatin and similar molecules.
MATERIALS AND METHODS

Proteins
Purified human angiostatin (≥98% pure as determined by SDS-PAGE) was purchased from Calbiochem, (La Jolla, CA). LPS from Escherichia coli 0111:B4 strain, TPA, plasminogen, and a lysine-sepharose binding fragment of plasminogen containing the first three kringle repeats (angiostatin-K1-3) were purchased from Sigma (St. Louis, MO). IL-8 was the kind gift of Dr. A. Proudfoot (Ares-Serono, Geneva, Switzerland) and the Sandoz Corp. (Vienna, Austria). MIP-2 and GROα were purchased from Peprotech (Rocky Hill, NJ). The lyophilized proteins were dissolved in phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin (BSA), aliquoted and stored at -80°C. Clarisco heparin was purchased from Schwarz Pharma (San Grato-Lodi, Italy). Formyl-Met-Leu-Phe (f-MLP) was purchased from Sigma, dissolved in dimethyl sulfoxide, aliquoted, and stored at -20°C.
Cells
To isolate neutrophils, freshly prepared buffy coats were diluted 1:3 in PBS and centrifuged three times at 180 ×g for 10 min to reduce contamination by platelets. After they were diluted further in PBS, cells were layered on Ficoll-Hypaque density gradient and centrifuged at 280 ×g for 30 min. Peripheral blood mononuclear cells were collected at the interface, and PBS and residual Ficoll were removed. The pellet, which contained erythrocytes and polymorphonuclear (PMN) leukocytes, was diluted with three volumes of ammonium chloride lysis solution (NH 4 Cl, 155 mM; KHCO 3 , 10 mM; EDTA 0.1 mM, pH 7.4) and incubated at 4°C for 10 min. After centrifugation (180xg for 10 min, 4°C) the lysis was repeated to eliminate residual erythrocytes. The final pellet was resuspended and used immediately for chemotaxis assays. Examinations of PMN preparations with light microscopy and flow cytometry using anti-CD 15 antibodies or May-Grunwald-Giemsa staining indicated in all cases that the purity of the preparations was always ≥96% neutrophils with <3-4% eosinophils. Control HL-60 and A549 cells expressing membrane-associated ATP synthase were cultured in RPMI 10% fetal calf serum. HL-60 cells were stimulated to differentiate toward a granulocyte phenotype by culture with 1 µM retinoic acid for 5 days.
Chemotaxis assays
Chemotaxis assay was performed according to Falk et al. (22) in 48-microwell chemotaxis chambers (Costar-Nucleopore, Milan, Italy), using 5-µm pore-size polyvinylpyrrolidone-free polycarbonate filters (Costar-Nucleopore). The lower compartment of each chamber was filled with 28 µl of chemoattractant; simple RPMI with 0.1% BSA (serum-free medium) was used as a control for random unstimulated migration. Cells were preincubated with angiostatin for 30 min at the indicated concentrations and then added to the wells in the upper chamber. Each well was filled with 50 µl of a cell suspension containing granulocytes (5×10 6 cell/ml) in serum-free medium. Each point was run in sestuplicate. The chambers were incubated for 45 min at 37°C in 5% CO 2 humidified atmosphere. The filters were then removed and the cells fixed with 100% ethanol and stained with toluidine blue. Cells that had not migrated were removed from the upper surface of the filter with filter paper. Migration was measured by densitometric analysis.
In vivo angiogenesis
The matrigel model of angiogenesis in vivo introduced by Passaniti et al. (23) and modified by Albini et al. (10) was used. Either IL-8, MIP-2, or GROα (at 50 ng/ml) or LPS (100 ng/ml) were added to liquid matrigel containing heparin at 4°C to a final volume of 0.6 ml. The matrigel suspension was slowly injected subcutaneously into the flanks of C57 black mice by using a cold syringe; in vivo the gel rapidly polymerized to form solid implants. Neutrophil depletion was performed by i.p. injection of the rat anti-mouse Ly-6G (Gr-1) monoclonal antibody (0.4 ml of a 1:50 dilution of ascites of RB6-8C5 hybridoma; kindly provided by R. L. Coffman, DNAX Research Institute, Palo Alto, CA). Mice were injected 2 days before and on the same day of matrigel injection. The efficiency of depletion was confirmed by hematoxylin staining of blood smears. Relative neutrophil counts averaged 15% of those of controls on day 0; this rose slowly to 21% on day 3 and to 37% on day 4 at the end of the experiment. Angiostatin, angiostatin-K1-3, or plasminogen was added directly into the matrigel at the concentrations indicated. Negative controls were matrigel suspensions without angiogenic factor, with or without angiostatin. For systemic administration, 300 µl of angiostatin-K1-3 (5 µg/ml in physiologic saline solution) were injected subcutaneously at three different locations twice daily. After 4 days, gels were collected and weighed. Samples were subjected to analysis of hemoglobin content as previously described (10) . In addition, some samples were embedded in paraffin and stained with hematoxylin and eosin for histological analysis or with an anti-myeloperoxidase antibody (Dako, Glostrup, Denmark) for histochemical identification of PMN and monocytes/macrophages.
Statistical analyses
Statistical analyses were performed using the Prism (Graphpad, San Diego, CA) program for ANOVA or t test comparisons.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNAs were isolated using the SV Total RNA Isolation System (Promega, Madison, WI) according to the manufacturer's instructions. Reverse transcription was performed with oligo dT primers or random hexamer primers and PCR amplified as described previously (24) using the following primers: ATP synthase α  sense: CATTGTGGACGTTCCAGTTG; antisense, TGACTGGCAAAGCAGTCAAG (product size: 701 bp); angiomotin sense, CTCTCGGCTCATCTCAAGAC; antisense, CCTTGTCCTCCACCCTCAAAA (product size: 797 bp); and β-actin positive controls as previously described (24) . cDNA was amplified with 35 cycles of 94-60-72 for 30 s each.
Flow cytometry analysis
Neutrophils isolated as decribed previously were stained with 5 µg/ml 7H10-BD4 antibody to the α subunit of ATP synthase (Molecular Probes, Eugene, OR) for 2 h at 4°C in RMPI with 0.1% BSA and 0.02% sodium azide to prevent internalization. This subunit is also expressed as part of the cell surface ATP synthase complex (25) . Staining was visualized with an FITC linked anti-mouse monoclonal secondary antibody (DAKO, Carpinteria, CA) at a 1:30 dilution for 45 min at 4°C in RMPI, 0.1% BSA, and 0.02% sodium azide. Staining was analyzed on a Coulter (Milan, Italy) EPICS flow cytometer set for granulocytes; samples treated identically, but without primary antibody, served as negative controls.
Tetrazolium salt (3-[4, 5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; MTT) assay
Granulocyte mitochondrial activity was determined using the MTT metabolic assay. PMN (2×10 5 cells/150 µl/well, 8 wells/sample) were seeded into 96-well culture plates (Corning, NY), in RPMI, 10% fetal calf serum in the presence of IL-8 (100 ng/ml) or fMLP (10 nM) and incubated for 24 h. A solution (50 µl) of MTT (2 mg/ml in PBS) preheated at 37°C was then added to each well and incubated for 4 h at 37°C in a humidified 5% CO 2 atmosphere. Mitochondria-reduced MTT forms insoluble blue formazan salts, which were solubilized in DMSO and read in a multiwell scanning spectrometer at a 540-nm wavelength.
RESULTS AND DISCUSSION
Inhibition of leukocyte migration in vitro by angiostatin
Angiostatin inhibition of angiogenesis has been observed in numerous preclinical models; however, the mechanism involved has not yet been fully elucidated. Most studies have focused on endothelial cell responses to angiostatin, with diverse effects reported, including up-regulation of E-selectin (26) , induction of apoptosis (3, 4, 27) , inhibition of t-PA-mediated plasmin activation (28) , blockage of VEGF-induced caveolin-1 production (29) , and binding to a cell-surface ATP synthase (21) . However, phagocytes appear to have an important, but often overlooked, role in angiogenesis (see refs 7, 17, 30, 31) . We have examined the effects of angiostatin on the migration of monocytes and neutrophils to specific chemotactic factors. Angiostatin (consisting of kringle repeats 1-4 of plasminogen) inhibited monocyte migration to chemoattractants such as MCP-1 and fMLP (Fig. 1 ) by approximately 25-50%, with inhibition reaching significance at high concentrations. An even stronger, dose-dependent angiostatin inhibition of PMN cell (>96% neutrophils) migration to the CXCR1 and CXCR2 agonist IL-8 was observed (Fig. 1) , with significant inhibition at 1.25-2.5 µg/ml. Similar results were obtained using agonists specific for CXCR2 as chemoattractants: MIP-2 ( Fig. 1) or GROα (data not shown). Because neutrophils appeared to have a higher sensitivity to angiostatin inhibition, and are key mediators of CXCR2 agonist-induced angiogenesis in vivo (see below), we chose to concentrate our studies on this cell type.
Angiostatin inhibition of neutrophil migration in vitro is specific
Plasminogen has been reported to bind to neutrophils (32) ; therefore, to test whether the effects on neutrophil migration were specific to angiostatin, we examined the activity of whole plasminogen and an angiostatin-like plasminogen fragment (angiostatin-K1-3). Neutrophil migration to MIP-2 was significantly inhibited by 2.5 or 5 µg/ml angiostatin, whereas an equimolar concentration of whole plasminogen (5.7 or 11.4 µg/ml) did not significantly affect migration (Fig. 1) . In contrast, angiostatin-K1-3, a plasminogen fragment containing the first three kringle repeats, known to have angiostatin-like activities (2), significantly inhibited neutrophil migration with a dose-dependence similar to angiostatin (Fig. 1) . These data confirm that the inhibition of neutrophil migration was specific for angiostatin and that the structural constraints that mediate this activity correlate with the known antiangiogenic activity of plasminogen fragments.
Angiostatin inhibits neutrophil migration to a broad range of chemoattractants
IL-8 and related chemokines activate several signal transduction pathways in neutrophils, which, in turn, can regulate extravasation, migration, and activation of inflammatory responses (33) . The principal mediators of neutrophil migration appear to be mitogenactivated protein (MAP) kinases and PI3K (34, 35) . TPA is a direct activator of MAP kinase not involving chemokine receptors, PI3K, or Raf transduction. We therefore tested whether angiostatin inhibited neutrophil migration to granulocyte chemoattractants that do not activate CXCR2. fMLP and the protein kinase C activator phorbol ester TPA also induced neutrophil migration that was significantly inhibited by angiostatin (Fig. 1) . The ability of angiostatin to inhibit TPA-induced granulocyte migration suggests that angiostatin treatment disturbs the MAP kinase pathway downstream of protein kinase C (36). The MEK kinase inhibitor PD98059, and, even more so, the p38 kinase inhibitor SB203580, both strongly inhibited neutrophil migration to IL-8 (data not shown), indicating a critical role in these pathways. The fundamental role of p38 in neutrophil migration is underlined by preclinical studies of p38 inhibitors as therapeutics for inflammatory pathologies (37) . Higher concentrations of angiostatin did not produce greater inhibition of PMN migration in vitro, independent of chemoattractant.
Neutrophils directly mediate CXCR2 ligand-induced angiogenesis in vivo
Several observations suggest that leukocytes and mast cells appear to play a significant role in angiogenesis, in particular angiogenesis associated with inflammation (9, 19, 31, 38, 39) . Furthermore, the chemokine IL-8 is a known angiogenic factor expressed by tumors that has been correlated with poor prognosis for several cancers, whose main cellular target are neutrophil granulocytes. IL-8 is a very strong chemoattractant for these cells (40) , suggesting that their recruitment is a principal effect in IL-8-induced angiogenesis. The IL-8 receptors CXCR1 (for which a murine homologue has not been found) and CXCR2, which is also a receptor for the chemokines MIP-2 and GROα, are expressed largely on neutrophils. Chemokines binding CXCR2 are also known as ELR CXC chemokines, because of the presence of this characteristic amino acid motif, and all are known to have potent angiogenic activity (41) .
In addition to expression on neutrophils, functional expression of CXCR2 has also been reported on some endothelial cells (42, 43) . We therefore examined the ability of these CXCR2 agonists to induce angiogenesis in vivo in normal, control, and neutropenic mice. In the matrigel implant model in vivo (13, 23) , IL-8, MIP-2, and GROα all induced potent angiogenic responses in normal control animals ( Fig. 2A and 2B ), with the mean hemoglobin level, a quantitative indicator of the angiogenic response, significantly higher than in negative control gels. Intraperitoneal injections of the rat anti-mouse Ly-6G (Gr-1) monoclonal antibody as previously described (44) induced a marked neutropenia (more than 80% fewer neutrophils) that was maintained over the course of the experiment. The strong angiogenic response to IL-8, MIP-2, or GROα observed in control animals was essentially absent in neutropenic animals, with significant differences between neutropenic and control animals with all three ligands ( Fig. 2A) . These data are consistent with previous studies (e.g., 16 ) and clearly indicate that neutrophils were necessary mediators of the angiogenic response induced by CXCR2 ligands in vivo in the matrigel sponge model used here.
Angiostatin inhibits angiogenesis induced by CXCR2 ligands in vivo
We then examined the ability of angiostatin to inhibit neutrophil-related angiogenesis in vivo. The addition of angiostatin to the matrigel sponge produced a dose-dependent, almost complete, inhibition of the strong angiogenic reaction in response to IL-8, MIP-2, or GROα (Fig. 2B) . The mean hemoglobin level was significantly lower in the negative controls and in gels also containing angiostatin at 0.5 and 2.5 µg/ml as compared with those with IL-8 alone. Similar significant inhibition by angiostatin was observed with MIP-2-or GROα-induced angiogenesis (Fig. 2B) . Consistent with the in vitro observations, equimolar concentrations of the angiostatin-K1-3 plasminogen fragment gave significant inhibition of angiogenesis in vivo, whereas inclusion of equimolar concentrations of whole plasminogen had little effect (Fig. 2B) . Furthermore, twice daily systemic subcutaneous administration of angiostatin-K1-3 also significantly inhibited MIP-2-induced angiogenesis (Fig. 2B) . Histological examination of the implants containing IL-8 or MIP-2 demonstrated the formation of dilated, hemorrhagic vessels and a massive infiltrate of leukocytes through the matrigel (Fig. 3A, 3C, and 3E ). The invasion of degranulating neutrophils often appears to precede and lead monocyte and endothelial cell migration in response to the angiogenic stimuli (10, 11) . Angiostatin (2.5 µg/ml) decreased the infiltration of inflammatory cells and the formation of blood vessels, with only a few cells having penetrated into the matrigel (Fig. 3B, 3D , and 3F), associated with small lacunae. Myeloperoxidase staining indicated a strong infiltration of neutrophils and monocytes/macrophages into the gels in response to IL-8 (Fig. 3C) . The few cells found in gels containing IL-8 and angiostatin were myeloperoxidase positive, indicating they were of either neutrophil or monocyte/macrophage origin (Fig. 3D) .
Angiostatin inhibits leukocyte recruitment and inflammation-related angiogenesis in vivo
LPS is a sign of bacteria intrusion recognized by phagocytes and one of the most powerful proinflammatory stimuli. Inclusion of LPS into the matrigel sponges injected in vivo as an inflammation model resulted in an intense leukocyte infiltrate (Fig. 3G) that was accompanied by a rapid and intense angiogenic response (Fig. 2B and 3G) , with poorly organized hemorrhagic vessels entering the gel. Addition of angiostatin along with the LPS dramatically reduced the leukocyte infiltrate (Fig. 3H) and significantly inhibited the angiogenic response (Fig. 2B) , indicating that angiostatin suppresses inflammation in vivo. These data provide further evidence of the link between angiogenic potential and leukocyte recruitment in vivo and the potent ability of angiostatin to counteract leukocyte infiltration and leukocyte-induced angiogenesis.
Angiostatin receptor expression by PMN and suppression of mitochondrial activity by angiostatin
The ability of angiostatin to inhibit PMN function in vitro and in vivo suggested that these cells may express receptors for angiostatin. One described angiostatin receptor is the cell surface ATP synthase (21) , which is active on endothelial cell surfaces and inhibited by angiostatin (25) . Angiomotin, a recently described protein that acts as an angiostatin receptor (20) , is apparently directly involved in chemotaxis and is inhibited by angiostatin. We tested neutrophils and HL-60-derived granulocytes for expression of ATP synthase mRNA. RT-PCR analysis demonstrated clear expression of the ATP synthase mRNA by PMN (Fig. 4A) . HL-60 also showed high expression of ATP synthase both as untreated leukemia cells and retinoic acid-differentiated granulocytes, as did the positive control A549 cancer cell line. Cell surface staining using antibodies recognizing the ATP synthase protein and flow cytometry analysis indicated that essentially all granulocytes (>98%) expressed ATP synthase protein on their surfaces (Fig. 4B) . In addition, neutrophils clearly expressed mRNA for angiomotin similar to the positive control human umbilical vein endothelium cells (Fig. 4C) . Thus neutrophils express mRNAs and protein for known angiostatin receptors, which may mediate the effects on angiostatin on these cells.
Previous studies have shown that granulocytes invading matrigel sponges were frequently degranulating (10, 11) , suggesting that PMN activation is also necessary for PMN-mediated angiogenesis. Neutrophil activation with stimulants such as fMLP and IL-8 leads to increased mitochondrial activity. Treatment with angiostatin significantly inhibited this activation of mitochondrial activity, with the response to IL-8 reduced fivefold and that to fMLP 2.7-fold (Fig. 4D) . Angiostatin inhibition of neutrophil mitochondrial activity after stimulation implies that the anti-inflammatory/angiogenic activity of this molecule may not only block migration, but also block neutrophil functions.
Our data suggest that in response to specific stimuli, such as CXCR2 ligands, an angiogenic cascade is engaged in which neutrophils play an essential role. Neutrophil entry and activation most likely results in local production of angiogenic factors such as VEGF (17) and on the release of proteases that stimulate angiogenesis and VEGF release, such as MMP-9 (18). This in turn recruits endothelial cells that then complete vessel formation.
The presence of inflammation in tumors has been known for more than a century; however, the potential role of these cells in promoting tumorigenesis and tumor growth has become appreciated only recently (31, 39) . Substantial literature indicates that PMNs have significant antitumor effects (see review in ref 45 ) that appear to play a key role in experimental tumor rejection. PMN effects seem to be chiefly mediated through production of reactive oxygen species that directly damage tumor cells as well as tumor vascular cells. They may also contribute to antibody-mediated tumor cell killing and TH1/TH2 skewing of the specific immune response, as well as production of antiangiogenic molecules such as angiostatin itself. However, these same processes may also promote tumorigenesis, for example, by oxidative damage to DNA and tumor growth, by supplying cytokines and enzymes that promote tumor angiogenesis. It may be assumed that most tumors by the time they are diagnosed in the clinic have already progressed and developed resistance to leukocytemediated tumor suppression. This implies that angiostatin inhibition of the proangiogenic effects of leukocytes would dominate over angiostatin inhibition of leukocyte antitumor activity.
Leukocytes can also release several proteinases that could potentially cleave plasminogen to angiostatin (46, 47) . Angiostatin inhibition of leukocyte recruitment might represent a physiological feedback mechanism for control of inflammatory angiogenesis, as suggested by angiostatin inhibition of neutrophil recruitment and angiogenesis in response to fMLP in vitro and LPS in vivo. Our data demonstrate that angiostatin or angiostatin mimics may be very effective antiinflammatory agents as well, broadening its potential clinical applications. Plasminogen alone (PLSG) at 5.7 µg/ml (equimolar relative to 2.5 µg/ml angiostatin) had little effect. Data from independent experiments were normalized and pooled by subtraction of mean random background migration to serum-free medium and given relative to mean positive controls (chemoattractant in the absence of inhibitor). Means ± SE are shown; asterisks indicate significant inhibition of migration relative to positive controls by ANOVA, with ***P < 0.0001, **P < 0.01, and *P < 0.05. The migration to the positive controls was always significantly higher than that to serum-free medium alone (ANOVA, P<0.0001). In animals made neutropenic (85% reduction of neutrophils) by injection of the rat anti-mouse Ly-6G (Gr-1) monoclonal antibody, these chemokines produced no angiogenic response. B) The addition of angiostatin to the gels significantly inhibited angiogenesis in vivo. (Nil: hemoglobin content in the absence of an angiogenic factor; angiostatin did not affect angiogenesis per se.) Inclusion of IL-8, MIP-2, GROα (50 ng/ml), or LPS (100 ng/ml) in the gels produced a strong angiogenic response (no inhibitor). The addition of angiostatin (doses are indicated in µg/ml, where not indicated, are at 2.5 µg/ml) or angiostatin-K 1-3 (Angio-K1-3, 1.9 µg/ml, equimolar to 2.5 µg/ml angiostatin) to the gels inhibited the angiogenic response. Plasminogen (PLSG, 5.7 or 11.4 µg/ml, equimolar to angiostatin at 2.5 or 5 µg/ml, respectively) did not show any effect. Subcutaneous administration of Angio-K1-3 also significantly inhibited angiogenesis. The data shown are pooled from independent experiments; means ± SE are shown. Significant inhibition of hemoglobin content relative to positive controls by ANOVA is indicated with asterisks: ***P < 0.0001, **P < 0.01, *P < 0.05; by t test (Mann-Whitney) is indicated with degree symbols: °°°P < 0.002, °°P < 0.02, °P <0 .05. -8 (a, c) induced a massive infiltrate of cells, many of which are myeloperoxidase-positive (c), with large, hemorrhagic vessels beginning to penetrate into the matrix. In the presence of angiostatin (2.5 µg/ml) (b, d), only a few cells penetrate into the matrix; most of these are myeloperoxidase-positive, leaving discrete lacunae. MIP-2 induced extensive vascularization of the sponges with large, relatively well-organized vessels along with extensive leukocyte infiltration (e). The presence of angiostatin (2.5 µg/ml) in gels containing MIP-2 essentially blocked the response, with few cells penetrating into the matrigel (f). Matrigel pellets implanted in vivo containing LPS showed a substantial infiltrate with large, poorly organized hemorrhagic vessels beginning to penetrate into the matrix (g). LPS with angiostatin (2.5 µg/ml) again blocked the response, with few cells penetrating into the matrigel (h). The bar is approximately 50 µm in a, b, and e-h and 12.5 µm in c and d. (PMN, >96% neutrophils) showed the expected amplified product similar to control (A549) cells. HL-60 cells, whether or not induced to differentiate with retinoic acid (+RA), also showed strong expression of the ATP synthase mRNA. All samples showed essentially equivalent amplification using primers for β-actin (data not shown), whereas no amplification was observed in negative controls (Control). B) Flow cytometery analysis of cell surface ATP synthase protein expression on neutrophils, using a monoclonal anti-ATP synthase primary antibody and monoclonal FITC linked anti-mouse secondary antibody. The granulocytes were >98% positive for cell surface ATP synthase protein (shaded profile) with respect to the negative control (open profile). C) RT-PCR of neutrophils and HL-60 cells for the angiomotin angiostatin receptor. Neutrophils (PMN, >96% neutrophils) showed the expected amplified product similar to control human umbilical vein endothelium cells. D) Neutrophil mitochondrial activity, as measured by the MTT assay, was clearly increased after treatment with fMLP or IL-8 for 24 h (control, black bars). The presence of angiostatin (Ast, 2.5 µg/ml, white bars) strongly inhibited this activation in both cases. Mean ± SD are shown, the differences between angiostatin-untreated and -treated samples were statistically significant, with P < 0.0001 (standard t test), for both IL-8 and fMLP.
